MYO1G promoter hypomethylation correlates with its mRNA expression, lymphocyte infiltration, and immunotherapy response in melanoma
ObjectivesMyosin IG (MYO1G) plays a vital role in triggering an immune response via regulating T cell migration to detect antigen-presenting cells. However, the biological and clinical significance of MYO1G DNA methylation and gene expression in melanoma and its immune microenvironment remains unkno...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1585450/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850214683575844864 |
|---|---|
| author | Yonghua Xia Yushu Zhang Chenxi Zheng Junbo Wang Wenyu Di Mengjie Zhang Minglei Yang |
| author_facet | Yonghua Xia Yushu Zhang Chenxi Zheng Junbo Wang Wenyu Di Mengjie Zhang Minglei Yang |
| author_sort | Yonghua Xia |
| collection | DOAJ |
| description | ObjectivesMyosin IG (MYO1G) plays a vital role in triggering an immune response via regulating T cell migration to detect antigen-presenting cells. However, the biological and clinical significance of MYO1G DNA methylation and gene expression in melanoma and its immune microenvironment remains unknown.Materials and methodsWe investigated and corroborated the correlations of MYO1G DNA methylation with gene expression, and clinicopathologic parameters in 461 melanomas from The Cancer Genome Atlas (TCGA). Subsequently, we associated MYO1G gene expression with overall survival in two independent cohorts including 94 immunotherapy-treated melanoma patients and 54 stage IV melanoma patients, respectively. Finally, the quantitative methylation-specific PCR (qMSP) assays were developed to measure the methylation levels of the cg22111043 and cg10673833 CpG sites located on MYO1G promoter region, and targeted bisulfite sequencing assay was used to validate accuracy of qMSP. We linked the methylation levels of the two CpG sites with MYO1G expression and progression-free survival in our cohort of 104 melanoma patients treated with immunotherapy. we used the AI-based cell segmentation and classification software Hover-Net to perform cell count and statistical analysis on the whole-slide images of pathology from 104 melanoma patients.ResultsWe observed that MYO1G gene expression exhibited a significantly inverse correlation with its promoter methylation. Moreover, hypomethylation in MYO1G promoter (corresponding to high gene expression level) was significantly associated with enhanced infiltration levels of immune cells (CD8+ T cell, M1 macrophage, activated natural killer cells estimated by gene expression), increased cytolytic activity, augmented expression level of immune checkpoint molecules (PDCD1, LAG3, CTLA4, CD274, BTLA, TIGIT, and HAVCR2) and favorable prognosis in melanoma. In the independent melanoma cohorts receiving immune checkpoint blockade treatment, high MYO1G expression was significantly linked to improved clinical outcome. In our cohort, patients with MYO1G promoter hypomethylation showed significantly elevated tumor-infiltrating lymphocytes level and prolonged progression-free survival after immunotherapy.ConclusionOur study highlights MYO1G promoter methylation as a key regulator of gene expression and a potential prognostic and predictive biomarker for immunotherapy response in melanoma. These findings offer new insights into the role of MYO1G in enhancing immune response in tumors. |
| format | Article |
| id | doaj-art-74dbcef5295c4308ae9328c5648de729 |
| institution | OA Journals |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-74dbcef5295c4308ae9328c5648de7292025-08-20T02:08:49ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-06-011510.3389/fonc.2025.15854501585450MYO1G promoter hypomethylation correlates with its mRNA expression, lymphocyte infiltration, and immunotherapy response in melanomaYonghua Xia0Yushu Zhang1Chenxi Zheng2Junbo Wang3Wenyu Di4Mengjie Zhang5Minglei Yang6The Department of Dermatovenereology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, ChinaThe Department of Dermatovenereology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, ChinaThe Department of Dermatology, Henan Second Provincial People’s Hospital, Zhengzhou, ChinaDepartment of Orthopedics, The First Affiliated Hospital of Xinxiang Medical University, Weihui, ChinaDepartment of Pathology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, ChinaThe Department of Dermatovenereology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, ChinaDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, ChinaObjectivesMyosin IG (MYO1G) plays a vital role in triggering an immune response via regulating T cell migration to detect antigen-presenting cells. However, the biological and clinical significance of MYO1G DNA methylation and gene expression in melanoma and its immune microenvironment remains unknown.Materials and methodsWe investigated and corroborated the correlations of MYO1G DNA methylation with gene expression, and clinicopathologic parameters in 461 melanomas from The Cancer Genome Atlas (TCGA). Subsequently, we associated MYO1G gene expression with overall survival in two independent cohorts including 94 immunotherapy-treated melanoma patients and 54 stage IV melanoma patients, respectively. Finally, the quantitative methylation-specific PCR (qMSP) assays were developed to measure the methylation levels of the cg22111043 and cg10673833 CpG sites located on MYO1G promoter region, and targeted bisulfite sequencing assay was used to validate accuracy of qMSP. We linked the methylation levels of the two CpG sites with MYO1G expression and progression-free survival in our cohort of 104 melanoma patients treated with immunotherapy. we used the AI-based cell segmentation and classification software Hover-Net to perform cell count and statistical analysis on the whole-slide images of pathology from 104 melanoma patients.ResultsWe observed that MYO1G gene expression exhibited a significantly inverse correlation with its promoter methylation. Moreover, hypomethylation in MYO1G promoter (corresponding to high gene expression level) was significantly associated with enhanced infiltration levels of immune cells (CD8+ T cell, M1 macrophage, activated natural killer cells estimated by gene expression), increased cytolytic activity, augmented expression level of immune checkpoint molecules (PDCD1, LAG3, CTLA4, CD274, BTLA, TIGIT, and HAVCR2) and favorable prognosis in melanoma. In the independent melanoma cohorts receiving immune checkpoint blockade treatment, high MYO1G expression was significantly linked to improved clinical outcome. In our cohort, patients with MYO1G promoter hypomethylation showed significantly elevated tumor-infiltrating lymphocytes level and prolonged progression-free survival after immunotherapy.ConclusionOur study highlights MYO1G promoter methylation as a key regulator of gene expression and a potential prognostic and predictive biomarker for immunotherapy response in melanoma. These findings offer new insights into the role of MYO1G in enhancing immune response in tumors.https://www.frontiersin.org/articles/10.3389/fonc.2025.1585450/fullimmune cell infiltrationpromoter methylationMYO1Gimmune checkpointimmunotherapy |
| spellingShingle | Yonghua Xia Yushu Zhang Chenxi Zheng Junbo Wang Wenyu Di Mengjie Zhang Minglei Yang MYO1G promoter hypomethylation correlates with its mRNA expression, lymphocyte infiltration, and immunotherapy response in melanoma Frontiers in Oncology immune cell infiltration promoter methylation MYO1G immune checkpoint immunotherapy |
| title | MYO1G promoter hypomethylation correlates with its mRNA expression, lymphocyte infiltration, and immunotherapy response in melanoma |
| title_full | MYO1G promoter hypomethylation correlates with its mRNA expression, lymphocyte infiltration, and immunotherapy response in melanoma |
| title_fullStr | MYO1G promoter hypomethylation correlates with its mRNA expression, lymphocyte infiltration, and immunotherapy response in melanoma |
| title_full_unstemmed | MYO1G promoter hypomethylation correlates with its mRNA expression, lymphocyte infiltration, and immunotherapy response in melanoma |
| title_short | MYO1G promoter hypomethylation correlates with its mRNA expression, lymphocyte infiltration, and immunotherapy response in melanoma |
| title_sort | myo1g promoter hypomethylation correlates with its mrna expression lymphocyte infiltration and immunotherapy response in melanoma |
| topic | immune cell infiltration promoter methylation MYO1G immune checkpoint immunotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1585450/full |
| work_keys_str_mv | AT yonghuaxia myo1gpromoterhypomethylationcorrelateswithitsmrnaexpressionlymphocyteinfiltrationandimmunotherapyresponseinmelanoma AT yushuzhang myo1gpromoterhypomethylationcorrelateswithitsmrnaexpressionlymphocyteinfiltrationandimmunotherapyresponseinmelanoma AT chenxizheng myo1gpromoterhypomethylationcorrelateswithitsmrnaexpressionlymphocyteinfiltrationandimmunotherapyresponseinmelanoma AT junbowang myo1gpromoterhypomethylationcorrelateswithitsmrnaexpressionlymphocyteinfiltrationandimmunotherapyresponseinmelanoma AT wenyudi myo1gpromoterhypomethylationcorrelateswithitsmrnaexpressionlymphocyteinfiltrationandimmunotherapyresponseinmelanoma AT mengjiezhang myo1gpromoterhypomethylationcorrelateswithitsmrnaexpressionlymphocyteinfiltrationandimmunotherapyresponseinmelanoma AT mingleiyang myo1gpromoterhypomethylationcorrelateswithitsmrnaexpressionlymphocyteinfiltrationandimmunotherapyresponseinmelanoma |